



# Announcement

---

Media Contacts:

Lisa Timothy  
External Affairs  
[lisa.timothy@msd.com](mailto:lisa.timothy@msd.com)

Amelia James  
External Affairs  
[Amelia.james@msd.com](mailto:Amelia.james@msd.com)

## **Announcement on Brexit preparations**

**Hoddesdon, September, 2019 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK))**

We are committed to acting responsibly in the interests of the patients which we serve, and our preparations for Brexit have been no different. Since the outcome of the EU referendum we have been working to ensure continuity of supply for patients under all scenarios, including that of a 'no deal' Brexit on 31<sup>st</sup> October. This has included establishing a Brexit project team dedicated to managing the necessary workload needed to fulfil the requirements and criteria laid out by UK and EU regulators.

To mitigate any disruption associated with Brexit, we have sought to prepare adequate stock build for all affected medicines and products across all impacted markets as well as undertaking a comprehensive evaluation of our distribution routes. Throughout this planning process we have followed and applied all recommendations contained within the preparedness notices published by the UK Government and the European Commission. This has involved regular dialogue with the relevant national regulatory bodies and agencies.

We are confident that our contingency plans across our business have been implemented effectively and will help to avoid any disruption to continuity of supply for all medicines and vaccines, and an uninterrupted conduct of clinical trials, as a consequence of Brexit.

Like all pharmaceutical companies, MSD does have supply constraints on products from time to time. These are entirely unrelated to Brexit and we have a standard procedure to ensure all healthcare professionals and regulators are aware of any potential supply issues as early as possible. We would encourage healthcare professionals to review our medicines supply page on the external MSD website for regular updates on the supply of all MSD medicines. For more information about the supply of MSD products, please contact customer services on: 01992 452094

~Ends~

### **About MSD**

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programmes and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit [www.msd-uk.com](http://www.msd-uk.com) and connect with us @MSDintheUK on [Twitter](#), [Instagram](#), [LinkedIn](#), [YouTube](#) and [Facebook](#).

### **Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA**

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate

fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2018 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ([www.sec.gov](http://www.sec.gov)).